Target intelligence / Profile preview

Cyclin D1 messenger RNA 3' untranslated region (CCND1 mRNA 3' UTR)

Target
CCND1 mRNA 3' UTR
Molecular classification
RNA, Untranslated region, Regulatory element
01

Overview

The Cyclin D1 (CCND1) messenger RNA 3' untranslated region (UTR) is a critical regulatory segment of the CCND1 transcript that controls the stability and translation of the Cyclin D1 protein (Source: NCBI Gene ID: 595). This region contains numerous binding sites for microRNAs (miRNAs), such as the miR-15/16 family, and RNA-binding proteins that normally act to repress Cyclin D1 expression (Source: Bentwich et al., Nature Genetics, 2005). In various malignancies, particularly mantle cell lymphoma and breast cancer, the 3' UTR often undergoes shortening through alternative polyadenylation or genomic deletions (Source: Wiestner et al., Blood, 2007). This loss of regulatory sequences allows the mRNA to escape miRNA-mediated degradation, leading to the constitutive overexpression of Cyclin D1 and subsequent uncontrolled cell cycle progression from G1 to S phase (Source: Mayr and Bartel, Cell, 2009). As a therapeutic target, the CCND1 mRNA 3' UTR is being explored for intervention using antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) designed to either degrade the transcript or block specific regulatory interactions (Source: Deshpande et al., Nature Reviews Drug Discovery, 2023). Targeting the mRNA directly offers a strategy to reduce protein levels at the source, potentially overcoming resistance mechanisms associated with downstream CDK4/6 inhibitors.

Other names
CCND1 3'-UTRCyclin D1 3' untranslated regionBCL1 mRNA 3' UTRPRAD1 mRNA 3' UTRCCND1 regulatory region
02

Mechanism of action

Sequence-specific binding to the 3' UTR to induce mRNA degradation via RNase H recruitment or to block interactions with stabilizing/destabilizing factors, thereby normalizing Cyclin D1 protein levels.

03

Biological functions

Post-transcriptional regulationmRNA stability regulationTranslation regulationCell cycle control
04

Disease associations

CancerMantle cell lymphomaBreast cancerMultiple myelomaB-cell lymphoma
05

Safety considerations

Off-target hybridization effectsInnate immune activation by synthetic oligonucleotidesSystemic delivery challenges to tumor tissuesPotential for compensatory upregulation of other D-type cyclins
06

Interacting drugs

Antisense oligonucleotides (investigational)

2 more in the full profile.

07

Biomarkers

CCND1 mRNA 3' UTR length (isoform analysis)Cyclin D1 protein expression (IHC)miR-15/16 expression levelsAlternative polyadenylation (APA) status

Beyond the preview

Go deeper on Cyclin D1 messenger RNA 3' untranslated region (CCND1 mRNA 3' UTR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclin D1 messenger RNA 3' untranslated region (CCND1 mRNA 3' UTR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call